Anaerobic bacteria mediated 'smart missile' targeting tumor hypoxic area enhances the therapeutic outcome of lung cancer

Tumor hypoxia is associated with a negative impact on the clinical treatment of lung cancer. Traditional therapeutic agents cannot be efficiently transported to tumor tissues, resulting in a reduced efficacy and serious toxic side effects. Therefore, the aim of this study is to propose a novel drug delivery strategy to solve this problem. The anaerobic Bifidobacterium infantis (B. infantis, Bi) is implanted in the hypoxic area of the tumor as the preimplanted target. The bacterial antibody decorated nano-drug missile (Ab-DOX-s-s-NPS) actively targets the interior of tumor tissue, and enriches therapeutic drug doxorubicin into tumor hypoxic area through bacterial recruitment. The study confirms that the increased concentration of Ab-DOX-s-s-NPS in tumor tissues through the recruitment of B. infantis plays an excellent anti-tumor effect, while the systemic side effects are significantly reduced, suggesting the good therapeutic effect of the B. infantis-mediated drug delivery strategy against lung cancer. Therefore, this work provides an elegant platform for the in vivo delivery of chemotherapeutic drugs to the hypoxic area of the tumor, representing a novel strategy potentially effective in the treatment of solid tumors.

Automated summary

Tumor hypoxia negatively affects the clinical treatment of lung cancer. This study proposes a novel drug delivery strategy by implanting anaerobic Bifidobacterium infantis as a preimplanted target and using bacterial antibody decorated nano-drug missiles to enrich therapeutic drugs in the tumor hypoxic area. The study confirms the excellent anti-tumor effect of this strategy, with reduced systemic side effects. This work provides an elegant platform for in vivo delivery of chemotherapeutic drugs to the hypoxic area of solid tumors.